Skip to main content
  • 43 Accesses

Abstract

For medicine today, the ultimate goal of most research-based pharmaceutical and allied health care organisations around the world is to discover, develop and procure necessary regulatory approvals for marketing new drugs for treatment or prevention of diseases in humans and animals. Drug discovery and development involves a complex process from early discovery of a chemical entity to demonstration of its safety and effectiveness for specific therapeutic indication(s). Introduction of new drugs either could be in the form of new chemical entities, or from regulatory perspectives a drug might be considered ‘new’ because of changes in its composition, route of administration, recommended dosage or dosage form. This chapter will deal primarily with pharmaceutical considerations for development of new chemical entities only, which usually require the greatest amount of investigation for safety and clinical evaluation to demonstrate their effectiveness. A comprehensive discussion of all pharmaceutical considerations in the design and development of all dosage forms or drug delivery systems for all routes of administration is beyond the scope of this chapter. An overview of critical pharmaceutical considerations for dosage forms generally developed for preclinical and early human testing will be covered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Amidon, G. L., Sinko, P. J. and Fleisher, D. (1988). Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res., 5, 651–4

    Article  CAS  PubMed  Google Scholar 

  • Anderson, B. D., Conradi, R. A. and Knuth, K. E. (1985a). Strategies in the design of solution-stable, water-soluble prodrugs. I. A physical-organic approach to promoiety selection for 21-esters of corticosteroids. J. Pharm. Sci., 74, 365–74

    Article  CAS  PubMed  Google Scholar 

  • Anderson, B. D., Conradi, R. A., Knuth, K. E. and Nail, S. L. (1985b). Strategies in the design of solution-stable, water-soluble prodrugs. II. Properties of micellar prodrugs of methylprednisolone. J. Pharm. Sci., 74, 375–81

    Article  CAS  PubMed  Google Scholar 

  • Anderson, B. D., Conradi, R. A., Spillman, C. H. and Forbes, A. D. (1985c). Strategies in the design of solution-stable, water-soluble prodrugs. III. Influence of the promoiety on the bioconversion of 21-esters of corticosteroids. J. Pharm. Sci., 74, 382–7

    Article  CAS  PubMed  Google Scholar 

  • Dighe, S. (1988). FDAs new policy on supplemental ANDAs for ‘BP’ rated products, requires in vivo bioequivalency data, may upgrade ratings to ‘AB’. FDC Reports, 50(39), 8

    Google Scholar 

  • Florence, A. T. (1981). In Yalkowsky, S. H. (Ed.), Techniques of Solubilization of Drugs, Marcel Dekker, New York, pp. 15–89

    Google Scholar 

  • Morris, M. E. (1978). Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J. Hosp. Pharm., 35, 669–72

    CAS  PubMed  Google Scholar 

  • Reed, K. W. and Yalkowsky, S. H. (1985). Lysis of human red blood cells in the presence of various cosolvents. J. Parenteral Sci. Tech., 39, 64–9

    CAS  Google Scholar 

  • Schroeder, H. G. and DeLuca, P. P. (1974). A study on the in vitro precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenteral Drug Ass., 28, 1–14

    CAS  Google Scholar 

  • Sinkula, A. A., Morozowich, W. and Rowe, E. L. (1973). Chemical modification of clindamycin: synthesis and evaluation of selected esters. J. Pharm. Sci., 62, 1106

    Article  CAS  PubMed  Google Scholar 

  • Wang, Y. J. and Korwal, R. R. (1980). Review of excipients and pHs for parenteral products used in the United States. J. Parenteral Drug Ass., 34, 452–62

    CAS  Google Scholar 

  • Yalkowsky, S. H. and Valvani, S. C. (1977). Precipitation of solubilized drugs due to injection or dilution. Drug Intell. Clin. Pharm., 11, 417–19

    CAS  Google Scholar 

  • Yalkowsky, S. H., Valvani, S. C. and Johnson B. W. (1983). In vitro method for detecting precipitation of parenteral formulations after injection. J. Pharm. Sci., 72, 1014–17

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Copyright information

© 1990 The editors and contributors

About this chapter

Cite this chapter

Valvani, S.C. (1990). The Pharmaceutical Background. In: O’Grady, J., Linet, O.I. (eds) Early Phase Drug Evaluation in Man. Palgrave, London. https://doi.org/10.1007/978-1-349-10705-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-349-10705-6_1

  • Publisher Name: Palgrave, London

  • Print ISBN: 978-1-349-10707-0

  • Online ISBN: 978-1-349-10705-6

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics